Company intelligence / Profile preview
Reconnect Labs
Winterthur, Switzerlandreconnect-labs.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Reconnect Labs has advanced a portfolio of rapid-onset, short-duration precision therapeutics for mental health. Their lead program—a sublingual formulation of DMT & Harmine for affective disorders—is in Phase II trials. Other programs include novel approaches to chronic pain and insomnia using psychoactive compounds with improved safety/tolerability profiles. The company also integrates digital diagnostic tools to enhance patient stratification and treatment outcomes.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (including next-generation psychedelic medicines)Precision neuropsychiatry therapeuticsRegenerative Therapeutics™ (proprietary term)Digital psychiatry tools as diagnostics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Reconnect Labs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reconnect Labs.